Otenabant

Otenabant is a drug that was under development by Pfizer for the treatment of obesity. It acts as a CB1 receptor antagonist.

History

Otenabant was developed by Pfizer in the early 2000s as a potential treatment for obesity. The drug works by blocking the CB1 receptor, which is involved in the regulation of appetite and energy balance in the body. However, the development of Otenabant was discontinued in 2008 due to concerns about side effects.

Mechanism of Action

Otenabant is a CB1 receptor antagonist. The CB1 receptor is found primarily in the brain and is involved in a variety of physiological processes, including appetite regulation and energy balance. By blocking this receptor, Otenabant is thought to reduce appetite and increase energy expenditure, thereby helping to reduce body weight.

Clinical Trials

Several clinical trials were conducted to evaluate the safety and efficacy of Otenabant in the treatment of obesity. However, the results of these trials were mixed, and the development of the drug was ultimately discontinued due to concerns about side effects.

Side Effects

The most common side effects reported in clinical trials of Otenabant included nausea, vomiting, and dizziness. There were also concerns about the potential for psychiatric side effects, including depression and suicidal thoughts.

Discontinuation

The development of Otenabant was discontinued in 2008. This decision was made due to concerns about the safety profile of the drug, particularly the potential for psychiatric side effects.

See Also

• Cannabinoid receptor antagonist
• Obesity
• Pfizer

Otenabant Resources
Latest articles Most recent articles Ongoing trials	Wikipedia